Interviews with eminent psychiatrists
Leo Sher, M.D. Today, we publish an interview with an eminent European psychiatrist, Dr. Jaanus Harro. Jaanus Harro, M.D., Ph.D. is Professor and Head of the Division of Neuropsychopharmacology at the Department of Psychology, University of Tartu, Estonia. He is also Clinical Supervisor of Neuropsychopharmacology and Drug Addiction at the Psychiatry Clinic, North Estonia Medical […]
Tejaswini Doifode, M.D., Raja Mogallapu, M.D., Steven Lippmann, M.D. Introduction Do you have patients addicted to shopping? Is it an addiction? Compulsive buying exists in nearly 6% of our population, predominantly among women (~80%) (1). Oniomania is the term that clinically describes compulsive shopping; it originates from Greek and comes from ṓnios- for “sale”, and […]
Interviews with eminent psychiatrists
Leo Sher, M.D. Today, we publish an interview with an eminent American psychiatrist, Dr. Steven Bernard Lippmann. Dr. Lippmann is Emeritus Professor of Psychiatry, University of Louisville School of Medicine, Louisville, Kentucky. Dr. Lippmann is retired, but remains an active volunteer physician faculty member, with teaching activities and lots of scientific writing. Dr. Lippmann sees […]
Leo Sher, M.D. A research report, “Effects of psilocybin therapy on personality structure” has been published in Acta Psychiatrica Scandinavica online ahead of print (1). The authors state that the goal of their study was to investigate whether psilocybin with psychological support modulates personality parameters in patients with treatment-resistant depression, to examine whether these alterations […]
Leo Sher, M.D. In May 2016, the U.S. Food and Drug Administration (FDA) announced regulations that require amendments to the existing supplement facts label, which uses units and conversions based on the 1968 Recommended Daily Allowances (RDA) (1). Vitamin A has previously been reported in international units (IU). New labeling rules require reporting of vitamin […]
Tallat Sultana, M.D., Steven Lippmann, M.D. Lofexidine Lofexidine is a newly released drug indicated for attenuating opioid withdrawal in the United States (1). A clonidine analogue and alpha 2-agonist, it has been prescribed in United Kingdom for this indication for decades (2). It reduces the signs and symptoms of withdrawal in animals and humans. With […]
Leo Sher, M.D. A research report, “Attempted suicide and oxytocin-related gene polymorphisms” has recently been published in the Journal of Affective Disorders (1). Oxytocin, a neuropeptide that plays a role in childbirth, lactation and attachment, has been a focus of studies related to suicidal ideation and behavior. It has been reported previously that a single-nucleotide […]
Leo Sher, M.D. Three days ago, a Centers for Disease Control and Prevention (CDC) report, “Vital Signs: Trends in State Suicide Rates – United States, 1999-2016 and Circumstances Contributing to Suicide – 27 States, 2015” was published (1). Suicide rates in the United States have risen nearly 30% since 1999. In this study, suicide rates […]
Leo Sher, M.D. Our research article, “Dehydroepiandrosterone and dehydroepiandrosterone sulfate levels in combat veterans with or without a history of suicide attempt” has been published in Acta Psychiatrica Scandinavica online ahead of print (1). The objective of our investigation was to test the hypothesis that combat veterans who have made a suicide attempt postdeployment can […]
Leo Sher, M.D. A RAND Corporation report, “Comparing quality of care in Veterans Affairs and non-Veterans Affairs settings” has been published in the Journal of General Internal Medicine (1). The Veterans Health Administration in the Department of Veterans Affairs (VA) is the largest integrated healthcare system in the United States. The goal of the study […]
